Nilotinib 300 Mg Twice Daily as First Line Treatment of Ph Positive Chronic Myeloid Leukemia In Chronic Phase Updated Results of the ICORG 0802 Phase 2 Study with Analysis of the GeneXpert System Versus IS BCR ABL RQ PCR

E. Conneally, R.T. Swords, F.J. Giles, Mary Frances McMullin, P. Le Coutre, S. Langabeer, M. Wieczorkowska, C. McDowell, B. Moulton, K. Egan, M.O. Dwyer

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)1404-1404
Number of pages1
Publication statusPublished - Dec 2010

Cite this